$157 million: AstraZeneca Introduces Early-stage COVID-19 Drug
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
$157 million: AstraZeneca Introduces Early-stage COVID-19 Drug
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
$157 million: AstraZeneca Introduces Early-stage COVID-19 Drug.
On May 17, AstraZeneca announced a partnership with RQ Biotechnology to introduce an early-stage novel coronavirus monoclonal antibody.
AstraZeneca will pay up to US$157 million for the exclusive global license of the drug. No specific information on the drug has been disclosed.
From: official website of the company
With the deal, London-based RQ Biotechnology announced on May 18. The company develops therapeutic and preventive therapies based on potent broad-spectrum monoclonal antibodies that provide immediate and long-lasting immunity to people at risk of serious illness or death from existing, emerging viral infections.
The management comes from well-known pharmaceutical companies or research institutions such as Sanofi, Pfizer, Imperial College London, and Oxford University.
Previously, AstraZeneca has a long-acting neutralizing antibody combination AZD7442 (Evusheld, Tixagevimab + Cilgavimab) approved for marketing, for severely immunocompromised adults and adolescents over the age of 12 and those who should not be vaccinated against the COVID-19 vaccine or immune response to the COVID-19 vaccine Pre-exposure prophylaxis for underrepresented populations.
The drug is the first neutralizing antibody combination approved for prevention, and has a long-acting advantage. A single intramuscular injection can achieve preventive immune protection for up to 12 months, which is more than 3 times that of ordinary neutralizing antibodies.
AZD7442 is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061), extracted from B cells of convalescent patients infected with SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020.
AstraZeneca utilizes its proprietary YTE half-life extension technology to optimize neutralizing antibodies to reduce Fc receptor and complement C1q binding for long-term effects.
Approval of the drug is based on data from the Phase III PROVENT study. The study included high-risk and immunocompromised subjects, more than 75% of whom had comorbidities. 5197 subjects were randomized 2:1 to receive 300 mg of AZD7442 (n = 3,460) or placebo (n = 1,737).
6-month follow-up data from prevention trials showed that a single intramuscular injection of the long-acting antibody combination reduced the risk of symptomatic COVID-19 by 83%; a separate treatment trial showed that treatment within three days of symptom onset reduces the risk of severe COVID-19 The risk of -19 or death was reduced by 88%.
In addition to the PROVENT study for prevention in high-risk patients, AstraZeneca started the Phase III TACKLE study in outpatients, announcing its positive results in mid-November 2021.
$157 million: AstraZeneca Introduces Early-stage COVID-19 Drug
(source:internet, reference only)
Disclaimer of medicaltrend.org
